Showing 4401-4410 of 9577 results for "".
- Study: Most Melanomas Don't Arise From Existing Moleshttps://practicaldermatology.com/news/study-most-melanomas-dont-arise-from-existing-moles/2458072/Less than one-third of melanomas (29 percent) arose from an existing mole, while the vast majority (71 percent) appeared on the skin as new spots, according to research in the Journal of the American Academy of Dermatology</
- Abeona Therapeutics Receives FDA Breakthrough Therapy Designation for EB-101 Autologous Cell Therapy in EBhttps://practicaldermatology.com/news/abeona-therapeutics-receives-fda-breakthrough-therapy-designation-for-eb-101-autologous-cell-therapy-in-eb/2458075/The U.S. Food and Drug Administration granted Breakthrough Therapy Designation status to the Abeona Therapeutics Inc.’s EB-101 gene therapy program for patients with Recessive Dystrophic Epidermolysis Bullosa. EB-101 is an autologous,&
- Modernizing Medicine To Add More Than 800 Jobs in Expansionhttps://practicaldermatology.com/news/modernizing-medicine-to-add-more-than-800-jobs-in-expansion/2458101/Modernizing Medicine will expand operations and add a total of 838 jobs by 2022. The expansion, to be implemented in the historic Boca Raton Innovation Center (BRIC) in Palm Beach County will result in a capital investment of more than $15 million in the Boca Raton community.
- FDA Expands Approval of Yervoy to Include Pediatric Patients 12 Years and Older with Unresectable or Metastatic Melanomahttps://practicaldermatology.com/news/fda-expands-approval-of-yervoy-to-include-pediatric-patients-12-years-and-older-with-unresectable-or-metastatic-melanoma/2458113/The FDA has expanded the indication for Bristol-Myers Squibb's Yervoy (ipilimumab) injection for intravenous use to now include the treatment of unresectable or metastatic melanoma in pediatric patients 12 years of age and older. Yervoy was evaluated in two trials of pediatric patients:
- LEO Pharma Receives EU Marketing Authorization for Kyntheum to Treat Plaque Psoriasishttps://practicaldermatology.com/news/leo-pharma-receives-eu-marketing-authorization-for-kyntheumfor-the-treatment-of-plaque-psoriasis/2458114/The European Commission has granted marketing authorisation for LEO Pharma's Kyntheum (brodalumab), a new biologic for the treatment of moderate-to-severe plaque psoriasis in adults within the European Union who are candidates for systemic therapy. Kyntheum selectively targets the IL-17 recep
- Array BioPharma Submits NDAs for Binimetinib and Encorafenib in Advanced Melanomahttps://practicaldermatology.com/news/array-biopharma-submits-ndas-for-binimetinib-and-encorafenib-in-advanced-melanoma/2458131/Array BioPharma submitted two New Drug Applications (NDAs) to the U.S. Food and Drug Administration (FDA) for the use of the combination of binimetinib 45 mg twice daily and encorafenib 450 mg once daily (COMBO450) for the treatment of patients with&nbs
- HydroLotion Scores National Eczema Association Seal of Acceptancehttps://practicaldermatology.com/news/hydrolotion-scores-national-eczema-association-seal-of-acceptance/2458138/Theraplex Company’s HydroLotion Daily Skin Moisturizer now has the National Eczema Association (NEA) Seal of Acceptance. The light-weight moisturizer for the face and body is hypoallergenic, noncomedogenic, and free of fragrances, preservatives
- Study Tallies Adverse Events Reported to FDA for Cosmeticshttps://practicaldermatology.com/news/study-tallies-adverse-events-reported-to-fda-for-cosmetics/2458144/There were 5,144 adverse events reported to the US Food and Drug Administration (FDA) for cosmetics and personal care products from 2004 to 2016, an average of 396 events per year, according to a new research letter published by
- New Personalized Medicine Approach May Help Treat Even the Most Challenging Woundshttps://practicaldermatology.com/news/new-personalized-medicine-approach-to-wound-healing-may-help-treat-even-the-most-challenging-wounds/2458172/An experimental treatment that allows the reprogramming of blood cells to promote the healing process of cutaneous wound may be beneficial in healing challenging wounds. “We discovered a way to modify specific white blood cells – the macrophages – and make them capable o
- BERG and debra of America Partner to Raise Awareness of EBhttps://practicaldermatology.com/news/berg-and-debra-of-america-partner-to-raise-awareness-of-eb/2458184/Biopharmaceutical company BERG and the non-profit patient advocacy group Dystrophic Epidermolysis Bullosa Research Association of America (debra of America) are partnering up to help patients and families affecte